Modified 2/1 Sunitinib Schedule May Be Safer in Renal Cell Carcinoma

Share this content:
Patients with metastatic renal cell carcinoma who transitioned to a modified 2/1 schedule of sunitinib experience an improved safety profile.
Patients with metastatic renal cell carcinoma who transitioned to a modified 2/1 schedule of sunitinib experience an improved safety profile.

Patients with metastatic renal cell carcinoma who transitioned to a modified 2/1 schedule of sunitinib experience an improved safety profile compared with that observed during the initial 4/2 schedule, a new study published online ahead of print in the journal Annals of Oncology has shown.

Patients receiving first-line sunitinib to treat metastatic renal cell carcinoma typically receive 4 weeks of treatment followed by 2 weeks off, but that schedule is often associated with relevant toxicities and related dose reductions. Therefore, researchers sought to evaluate the safety profile of an alternative schedule, 2 weeks on and 1 week off.

For the study, researchers retrospectively analyzed data from 249 patients with metastatic renal cell carcinoma who received first-line treatment with sunitinib.

Of those, 208 initiated sunitinib on the 4/2 schedule and then transitioned to the 2/1 schedule due to toxicity and 41 patients started with sunitinib on the 2/1 schedule.

Researchers compared the safety of those patients with 211 patients treated with the 4/2 schedule at another institution.

Results showed that among those who started on the 4/2 schedule and switched to the 2/1 schedule, the overall incidence of grade 3 or higher toxicities was significantly reduced from 45.7% to 8.2% (P<0.001). 

RELATED: Standard for Detecting Occult Bone Mets in Renal Cell Carcinoma May Not Be Optimal

Researchers found that the incidence of fatigue, hypertension, hand-foot syndrome, and thrombocytopenia were less common with the 2/1 schedule.

In regard to efficacy, median progression-free survival was 30.2 months in the group that switched schedules, 10.4 months in the 2/1 group, and 9.7 months in the 4/2 group.

Reference

  1. Bracarda S, Iacovelli R, Boni L, et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol. 2015. [epub ahead of print]. doi: 10.1093/annonc/mdv315.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters